Azenta, Inc. (AZTA) as of March 31, 2026 presents a balance sheet where MFFAIS reports a cash liquidation value (CLV) of negative $78.9 million, a liquid liquidation value (LLV) of $52.4 million, and an operating liquidation value (OLV) of $131.0 million. The dominant balance-sheet event this quarter is a $149.1 million non-cash goodwill impairment charge ($112.4 million in Multiomics, $36.6 million in SMS), triggered by a sustained stock price decline and downward revision to forecasted cash flows. This charge partially depleted the retained earnings balance ($1.24 billion) and reduced reported stockholders' equity from the prior quarter's $1.7 billion to $1.55 billion. Under the liquidation lens, goodwill ($553.1 million carrying value post-impairment) receives a 0% recovery haircut, representing the single largest source of liquidation value destruction. Net intangible assets of $91.4 million ($363.1 million gross less $271.6 million accumulated amortization) similarly receive 0% recovery. Together, goodwill and net intangibles total $644.5 million of balance sheet assets that contribute zero to liquidation recovery. On the asset side, liquid instruments are the primary recovery source: cash and equivalents of $234.0 million (100% recovery), plus marketable securities of $324.3 million (short and long-term, predominantly U.S. government and highly rated corporate debt, effectively 100% recovery), plus restricted cash of $6.5 million. AR net of allowance is $131.3 million ($4.5 million allowance against gross; 90-95% recovery yields approximately $118-125 million). Inventory of $78.5 million with a $7.7 million reserve embedded (60% recovery yields approximately $47 million). PP&E net of $171.8 million (50-70% recovery yields approximately $86-120 million). Assets held for sale related to B Medical Systems are $145.6 million ($77.2 million current, $68.4 million noncurrent); the pending sale to Thelema S.À R.L. did not close by the March 31, 2026 deadline due to the buyer's financing failure. A $9.0 million deposit has been received; if the deal terminates, Azenta retains $5.0 million as a break-up fee. The liability stack is relatively lean: no long-term debt outstanding; total liabilities of $349.2 million including $257.2 million current (accounts payable $33.1 million, accrued compensation $29.1 million, deferred revenue $39.0 million, derivative liabilities $29.6 million, income taxes payable $8.8 million, discontinued operations current liabilities $31.4 million). Operating lease obligations (noncurrent) of $55.7 million remain at face value in liquidation. Three unresolved material weaknesses in internal controls (cash flow statement, account reconciliations, expense classification) add financial reporting risk but do not directly alter the asset or liability stack. Non-cancellable purchase commitments of $41.1 million are an off-balance-sheet liability at face in a wind-down. The goodwill impairment confirms that the carrying value of both reporting units exceeds fair value, consistent with the CLV being negative when intangible-heavy assets are zeroed out.
▼ Community Notes